Table 3: 25(OH)D serum concentration and number (%) of subjects who did not reach the target levels of 20 ng/mL and 30 ng/mL at all time points.

Visit 1
(week 2)
Visit 2
(week 0)
Visit 3
(week 2)
Visit 4
(week 4)
Visit 5
(week 8)
Visit 6
(week 12)

Group 125(OH)D Mean ± SD (min–max)7.62 ± 2.11
(4.0–12.0)
9.08 ± 3.37
(4.0–19.0)
21.00 ± 5.97
(11.0–46.0)
26.93 ± 7.54
(14.0–45.0)
28.25 ± 8.31
(10.0–45.0)
28.63 ± 8.08
(13.0–49.0)
n (%) with 25(OH)D ≤ 20 ng/mL40 (100)38 (95)21 (52)9 (22)6 (15)6 (15)
n (%) with 25(OH)D ≤ 30 ng/mL40 (100) 40 (100) 37 (92) 27 (67) 26 (65) 25 (62)
Group 225(OH)D Mean ± SD (min–max)13.72 ± 2.63
(8.0–20.0)
15.30 ± 3.38
(7.0–23.0)
25.55 ± 5.89
(12.0–41.0)
31.65 ± 7.60
(18.0–50.0)
28.15 ± 7.69
(14.0–46.0)
30.10 ± 8.15
(13.0–50.0)
n (%) with 25(OH)D ≤ 20 ng/mL40 (100)35 (87)8 (20)1 (2)7 (17)3 (7)
n (%) with 25(OH)D ≤ 30 ng/mL40 (100) 40 (100) 35 (87) 20 (50) 27 (67) 24 (60)
Group 325(OH)D Mean ± SD (min–max)24.88 ± 2.75
(21.0–30.0)
24.38 ± 5.31
(12.0–38.0)
32.88 ± 5.63
(20.0–51.0)
33.90 ± 8.24
(24.0–62.0)
35.25 ± 7.22
(23.0–54.0)
33.90 ± 8.21
(5.0–50.0)
n (%) with 25(OH)D ≤ 20 ng/mL0 (0)10 (25)1 (2)0 (0)0 (0)1 (2)
n (%) with 25(OH)D ≤ 30 ng/mL40 (100) 36 (90) 14 (35) 14 (35) 12 (30) 10 (25)
Group 425(OH)D Mean ± SD (min–max)38.21 ± 6.11
(31.0–51.0)
32.70 ± 10.01
(11.0–53.0)
34.85 ± 8.25
(21.0–56.0)
35.65 ± 10.49
(17.0–55.0)
36.25 ± 11.90
(20.0–67.0)
35.15 ± 13.37
(11.0–68.0)
n (%) with 25(OH)D ≤ 20 ng/mL0 (0)3 (15)0 (0)2 (10)1 (5)1 (5)
n (%) with 25(OH)D ≤ 30 ng/mL0 (0) 6 (30) 7 (35) 2 (10) 8 (40) 9 (45)
Placebo group
(group 5 + 6 + 7 + 8)
25(OH)D Mean ± SD (min–max)18.83 ± 10.89
(6.0–50.0)
19.09 ± 9.43
(5.0–42.0)
18.57 ± 8.48
(6.0–43.0)
19.06 ± 9.34
(6.0–39.0)
19.17 ± 9.41
(4.0–38.0)
20.74 ± 9.48
(4.0–39.0)
n (%) with 25(OH)D ≤ 20 ng/mL20 (57)19 (54)21 (60)21 (60)21 (60) 19 (54)
n (%) with 25(OH)D ≤ 30 ng/mL30 (86)31 (89)33 (94)29 (83)30 (86)30 (86)